Salix Pharmaceuticals (NASDAQ:SLXP) is a specialist pharmacy company that develops, acquires and commercializes prescription drugs, and medical devices used in the treatment of various forms of GI diseases. Gastrointestinal, or GI, disease is one of the most widespread diseases in the U.S., and it results in substantial morbidity, mortality, and healthcare costs. The most prevalent form of these diseases are non-food-borne gastroenteritis, GI infections, food borne illness, gastro esophageal reflux disease, gallbladder disease, irritable bowel syndrome, and opioid-induced constipation.
Salix offers tablets such as Xifaxan, Moviprep, Osmoprep, Apriso, Giazo, Colazal, Fulyzaq, Solesta, Deflux, etc.
Currently Salix is gaining traction with its drugs -- Relistor and Xifaxan, which are awaiting FDA approval. However due to the uncertainty surrounding the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|